RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares.

Keep Reading →